Zhejiang Huahai Pharmaceutical (SHA:600521) said four of its drugs were proposed for selection for twelfth batch of China's National Centralized Drug Procurement Program, according to a Monday disclosure on the Shanghai bourse.
The drugs are lamotrigine tablets, a treatment for epilepsy, iguratimod tablets, a treatment for active rheumatoid arthritis, hyper tension drug perindopril/amlodipine tablets (III) and mesalazine enteric-coated tablets, a drug for ulcerative colitis and Crohn's disease.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.